BRD4 and colorectal carcinoma: Enhanced BRD4 protein stability weakens its binding ability to BET inhibitors, induces chromosome remodeling, promotes proto-oncogene enhancer activity, and ultimately leads to CRC resistance to BETis and increased tumor malignancy.